Behavioral Intervention for CMV in Pregnancy
Trial Summary
What is the purpose of this trial?
This study will evaluate whether a brief prenatal clinic-based cytomegalovirus (CMV) risk-reduction behavioral intervention will prevent maternal CMV infections during pregnancy in women.
Will I have to stop taking my current medications?
The trial does not specify if you need to stop taking your current medications, but it excludes those planning to use immune globulin, ganciclovir, or valganciclovir. If you are on these medications, you may need to stop them to participate.
What data supports the effectiveness of the treatment for CMV prevention in pregnancy?
The research titled 'A Brief Prenatal Intervention of Behavioral Change to Reduce the Risk of Maternal Cytomegalovirus: A Randomized Controlled Trial' suggests that a brief prenatal behavioral intervention can help reduce risk behaviors associated with maternal CMV infection, indicating potential effectiveness of the treatment.12345
How is the CMV Risk-Reduction Intervention treatment different from other treatments for CMV in pregnancy?
The CMV Risk-Reduction Intervention is unique because it focuses on behavioral changes to reduce the risk of CMV infection during pregnancy, rather than using medication. This approach is similar to cognitive-behavioral interventions used for preventing perinatal depression, emphasizing education and behavior modification to prevent disease.23678
Research Team
Karen B Fowler
Principal Investigator
University of Alabama at Birmingham
Eligibility Criteria
This trial is for pregnant women who are early in their prenatal care (before 20 weeks gestation) and have tested negative or nonprimary positive for CMV. It's not suitable for those planning to deliver outside of the University of Alabama at Birmingham hospital, with known major fetal anomalies, planned pregnancy termination, or use of certain antiviral drugs.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Intervention
Participants receive either a CMV risk-reduction intervention or stress-reduction messaging, including a one-on-one session, a video, a take-home packet, and weekly text messages for 12 weeks
Follow-up
Participants attend follow-up visits at 6 and 12 weeks for specimen collection and assessment of intervention outcomes
Monitoring until Delivery
Participants are monitored for CMV viral loads, seroconversion, and reinfections until delivery, with specimen collection at various intervals
Treatment Details
Interventions
- CMV Risk-Reduction Intervention
- Stress Reduction Messaging
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of Alabama at Birmingham
Lead Sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Collaborator